Substances of plant origin are chemically unstable and easily oxidized by external conditions. However, they have to remain in their bioactive form when they are used in food, pharmaceutical, nutraceutical and cosmetic industries. Encapsulation method is an effective technique that should protect them preventing the degradation of these active substances and thus prevent them from losing their activities. In this review, the strategies for encapsulating plant substances and their preparation methods including emulsification, atomization, coaxial electrospray system, lyophilization, coacervation, in situ polymerization, melt extrusion, supercritical fluid technology, fluidized bed coating etc. were discussed. The release mechanisms of plant active substances were also presented. The choice of an appropriate encapsulation technique and wall material depends on the final use of the product and the processing conditions involved. The use of liposomes, ethosomes, phytosomes, emulsions, microspheres, microcapsules, solid lipid nanoparticles including formulations based on plant substances has enhanced their therapeutic effects. With the use of all these encapsulation systems, the formulation is delivered in a targeted manner, giving it an on-site effect, and the bioavailability of the formulation is also improved. With these new drug delivery systems, actives and extracts used in herbal formulations exhibit improved stability, sustained release from the formulation, protection against toxicity, and improved therapeutic efficacy. Keywords : nanoparticles, bioactive substance, formulation
{"title":"Encapsulation Methods and Releasing Mechanisms of Encapsulated Active Drug","authors":"Kakwokpo Clémence N’GUESSAN-GNAMAN, Nakognon Awa TUO-KOUASSI, Ismael Dally, Sandrine AKA-ANY-GRAH, Rosine Désirée CHOUGOUO KENGNE-NKUITCHOU, A. Lia, Apo Laurette Anin, Alain N’GUESSAN","doi":"10.22270/jddt.v14i1.6356","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6356","url":null,"abstract":"Substances of plant origin are chemically unstable and easily oxidized by external conditions. However, they have to remain in their bioactive form when they are used in food, pharmaceutical, nutraceutical and cosmetic industries. Encapsulation method is an effective technique that should protect them preventing the degradation of these active substances and thus prevent them from losing their activities. \u0000In this review, the strategies for encapsulating plant substances and their preparation methods including emulsification, atomization, coaxial electrospray system, lyophilization, coacervation, in situ polymerization, melt extrusion, supercritical fluid technology, fluidized bed coating etc. were discussed. The release mechanisms of plant active substances were also presented. \u0000The choice of an appropriate encapsulation technique and wall material depends on the final use of the product and the processing conditions involved. The use of liposomes, ethosomes, phytosomes, emulsions, microspheres, microcapsules, solid lipid nanoparticles including formulations based on plant substances has enhanced their therapeutic effects. With the use of all these encapsulation systems, the formulation is delivered in a targeted manner, giving it an on-site effect, and the bioavailability of the formulation is also improved. With these new drug delivery systems, actives and extracts used in herbal formulations exhibit improved stability, sustained release from the formulation, protection against toxicity, and improved therapeutic efficacy. \u0000Keywords : nanoparticles, bioactive substance, formulation","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":"16 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139529578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6244
Pratima Chourasiya, Rekha Gour, Anant K. Patel
The study focused on evaluating the acute toxicity and phytochemical composition of Curcuma longa leaves using Swiss albino mice. The investigation involved a two-phase acute toxicity test, with doses up to 5000 mg/kg administered orally. The results indicated no toxicity at lower doses, while signs of weakness, salivation, and reduced movement were observed at 1600 mg/kg. Lethal effects were noted at 5000 mg/kg, establishing the LD50 at 2154.06 mg/kg. Phytochemical analysis revealed the presence of alkaloids, flavonoids, glycosides, tannins, and volatile oils in the ethanolic extract. The extract exhibited a 27.37% yield, characterized by a yellowish-orange color and a sticky consistency. This comprehensive investigation sheds light on both the acute toxicity profile and the diverse phytochemical components presents in Curcuma longa leaves. Keywords: Curcuma longa, Phytoconstituent, Acute oral toxicity, Lokes method.
{"title":"Qualitative Phytochemical Investigation and Acute Oral Toxicity Study on Ethanolic Extract of Curcuma longa Leaves","authors":"Pratima Chourasiya, Rekha Gour, Anant K. Patel","doi":"10.22270/jddt.v14i1.6244","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6244","url":null,"abstract":"The study focused on evaluating the acute toxicity and phytochemical composition of Curcuma longa leaves using Swiss albino mice. The investigation involved a two-phase acute toxicity test, with doses up to 5000 mg/kg administered orally. The results indicated no toxicity at lower doses, while signs of weakness, salivation, and reduced movement were observed at 1600 mg/kg. Lethal effects were noted at 5000 mg/kg, establishing the LD50 at 2154.06 mg/kg. Phytochemical analysis revealed the presence of alkaloids, flavonoids, glycosides, tannins, and volatile oils in the ethanolic extract. The extract exhibited a 27.37% yield, characterized by a yellowish-orange color and a sticky consistency. This comprehensive investigation sheds light on both the acute toxicity profile and the diverse phytochemical components presents in Curcuma longa leaves. \u0000Keywords: Curcuma longa, Phytoconstituent, Acute oral toxicity, Lokes method.","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":"28 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adult onset Still’s disease (AOSD) is a rare clinical entity with unknown etiology, characterized by arthritis, fever, evanescent rash, and other systemic presentations. AOSD generally does not overlap with other rheumatic diseases. AOSD is a diagnosis by exclusion, and it is one of the common causes of pyrexia of unknown origin (PUO) which can be life-threatening if mistreated. Although steroids are the first line of therapy, about 20%-30% of patients are refractory, intolerant, and or relapse during tapering or upon discontinuation of steroids. There are no clinical guidelines in treating such patients, which is challenging. Keywords: Still’s disease, arthritis, fever, auto-inflammatory
{"title":"Adult Onset Still’s Disease in a Patient with Fever of Unknown Origin: A Rare Case","authors":"Silky Kumari, Subhankar Das, Sudha Kumari, Gyan Ranjan, Mahaprasad Barik, Ramya Ranjan Kanta, Somnath Nishad","doi":"10.22270/jddt.v14i1.6201","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6201","url":null,"abstract":"Adult onset Still’s disease (AOSD) is a rare clinical entity with unknown etiology, characterized by arthritis, fever, evanescent rash, and other systemic presentations. AOSD generally does not overlap with other rheumatic diseases. AOSD is a diagnosis by exclusion, and it is one of the common causes of pyrexia of unknown origin (PUO) which can be life-threatening if mistreated. Although steroids are the first line of therapy, about 20%-30% of patients are refractory, intolerant, and or relapse during tapering or upon discontinuation of steroids. There are no clinical guidelines in treating such patients, which is challenging. \u0000Keywords: Still’s disease, arthritis, fever, auto-inflammatory","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":"15 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aims to develop and test a topical drug delivery system for antihypertensive activity using Losartan potassium-loaded niosomes. The niosomes were created using the traditional ether injection approach, with four formulations made using cholesterol as the lipid and varying quantities of surfactants such as span 80 and span 60. The different formulations underwent testing for FTIR, particle size, zeta potential, drug content, entrapment efficiency, and in vitro release. FTIR analysis revealed that the medication was incompatible with excipients. The study concludes by highlighting current obstacles and future possibilities for the development of niosomes as effective vehicles. Overall, this analysis provides insight into the potential of niosomes in medication delivery and encourages further research in this field. Keywords: Losartan potassium, Antihypertensive, Niosomes, Tween 80 and Span 20
{"title":"Formulation and In Vitro Evaluation of Niosomal Gel for The Topical Administration of Losartan Potassium","authors":"Ruthika Ratna Veni Marri, Mandeti Nithisha, Mamidipalli Apurva, Raghavarapu Prasanthi, Tirunagari Mamatha","doi":"10.22270/jddt.v14i1.6366","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6366","url":null,"abstract":"This study aims to develop and test a topical drug delivery system for antihypertensive activity using Losartan potassium-loaded niosomes. The niosomes were created using the traditional ether injection approach, with four formulations made using cholesterol as the lipid and varying quantities of surfactants such as span 80 and span 60. The different formulations underwent testing for FTIR, particle size, zeta potential, drug content, entrapment efficiency, and in vitro release. FTIR analysis revealed that the medication was incompatible with excipients. The study concludes by highlighting current obstacles and future possibilities for the development of niosomes as effective vehicles. Overall, this analysis provides insight into the potential of niosomes in medication delivery and encourages further research in this field. \u0000Keywords: Losartan potassium, Antihypertensive, Niosomes, Tween 80 and Span 20","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139623063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6370
Hope K Fiadjoe, G. Koffuor
Introduction: While the efficacy of Blighia unijugata against various conditions has been scientifically validated, very little is known of its safety in normal rats. This study aimed to assess the toxic effects of the ethanolic stem bark extract of Blighia unijugata (EBU) on body and organ weight, biochemistry, and hematology of Sprague Dawley rats following repeated oral administration. Method: Twenty (20) male Sprague-Dawley rats were randomly selected into four groups (n = 5) and administered distilled water or EBU at doses of 50, 100, or 200 mg/kg respectively for 28 days. For each group, percentage changes in body and organ weight, serum lipid profile, fasting blood glucose levels, liver, and kidney functions, and the various hematological variables were determined. Results: EBU treatment (50-200 mg/kg body weight) caused no significant changes (p>0.05) in the body weight and the relative organ weight of the heart, kidney, and spleen. Similarly, no significant changes (p>0.05) were observed in the lipid profile (Total Cholesterol, Triglycerides, High-Density Lipoproteins, Low-Density Lipoproteins, and Very Low-Density Lipoproteins), fasting blood glucose, serum urea, creatinine, albumin, globulin, total protein, total bilirubin, alanine aminotransferase, aspartate aminotransferase, and the hematological measures, except for a significant reduction (p ≤ 0.05) in Alkaline Phosphatase after treatment with 200 mg/kg EBU. Conclusion: Overall, this investigation underscores that EBU administration did not cause significant effects on the evaluated parameters, suggesting relative safety within the experimental conditions. However, for potential clinical trials and human use, additional studies such as chronic toxicity assessments across diverse animal models and dosage ranges are recommended. Keywords: Blighia unijugata; biochemistry, hematology, body weight, organ weight
{"title":"Effect of ethanolic stem-bark extract of Blighia unijugata on body and organ weight, biochemistry, and hematology in Sprague-Dawley rats","authors":"Hope K Fiadjoe, G. Koffuor","doi":"10.22270/jddt.v14i1.6370","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6370","url":null,"abstract":"Introduction: While the efficacy of Blighia unijugata against various conditions has been scientifically validated, very little is known of its safety in normal rats. This study aimed to assess the toxic effects of the ethanolic stem bark extract of Blighia unijugata (EBU) on body and organ weight, biochemistry, and hematology of Sprague Dawley rats following repeated oral administration. \u0000Method: Twenty (20) male Sprague-Dawley rats were randomly selected into four groups (n = 5) and administered distilled water or EBU at doses of 50, 100, or 200 mg/kg respectively for 28 days. For each group, percentage changes in body and organ weight, serum lipid profile, fasting blood glucose levels, liver, and kidney functions, and the various hematological variables were determined. \u0000Results: EBU treatment (50-200 mg/kg body weight) caused no significant changes (p>0.05) in the body weight and the relative organ weight of the heart, kidney, and spleen. Similarly, no significant changes (p>0.05) were observed in the lipid profile (Total Cholesterol, Triglycerides, High-Density Lipoproteins, Low-Density Lipoproteins, and Very Low-Density Lipoproteins), fasting blood glucose, serum urea, creatinine, albumin, globulin, total protein, total bilirubin, alanine aminotransferase, aspartate aminotransferase, and the hematological measures, except for a significant reduction (p ≤ 0.05) in Alkaline Phosphatase after treatment with 200 mg/kg EBU. \u0000Conclusion: Overall, this investigation underscores that EBU administration did not cause significant effects on the evaluated parameters, suggesting relative safety within the experimental conditions. However, for potential clinical trials and human use, additional studies such as chronic toxicity assessments across diverse animal models and dosage ranges are recommended. \u0000Keywords: Blighia unijugata; biochemistry, hematology, body weight, organ weight","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 35","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6336
Leema Lobo, N. Kishore, Manjari Sharma
The critical importance of phosphate regulation in chronic kidney disease (CKD) has been well understood for decades. But new findings, frequently applicable to routine medical care, continue to evolve. Poor health outcomes, greater morbidity, lowered quality of life, and a higher death rate from cardiovascular disease are all linked to the development of CKD-bone mineral ailment. Increased blood phosphate levels are linked to an increased risk of mortality in hemodialysis patients due to changes in phosphate breakdown and declining renal function as CKD advances.In this setting, according to CKD-mineral bone disease recommendations, it is critical to regulate serum phosphate levels in patients with CKD-mineral bone problem. If dialysis and dietary intervention fail to control blood phosphate levels, the use of phosphate binders is advised. Although phosphate binders are successful in lowering blood phosphate levels by actively binding to dietary phosphate, certain individuals have adverse effects that may restrict their use.These medications also have a significant pill load, which might result in poor treatment compliance. Tenapanor, a novel medication, works by inhibiting the sodium/hydrogen exporter isoform 3 (NHE3), which lowers intestinal phosphate absorption primarily by decreasing passive paracellular phosphate flow. Tenapanor also reduces the expression of the sodium phosphorus 2b transport protein (NaPi2b), which limits active transcellular phosphate absorption compensation. This is considered to be more effective phosphorous absorption regulator and a better target for tailored medication therapy. This clinical study aggregate report explores the currently published studies that have evaluated Tenapanor for the treatment of hyperphosphatemia in end stage renal disease patients on haemodialysis. Keywords: Tenapanor, phosphate binding agents, hyperphosphatemia, chronic kidney disease, phosphate control, phosphate binders, phosphate absorption, phosphate absorbtion inhibitor.
{"title":"Tenapanor-A Novel Approach for Management of Hyperphosphatemia in End Stage Renal Disease: A Clinical Study Aggregate Review","authors":"Leema Lobo, N. Kishore, Manjari Sharma","doi":"10.22270/jddt.v14i1.6336","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6336","url":null,"abstract":"The critical importance of phosphate regulation in chronic kidney disease (CKD) has been well understood for decades. But new findings, frequently applicable to routine medical care, continue to evolve. Poor health outcomes, greater morbidity, lowered quality of life, and a higher death rate from cardiovascular disease are all linked to the development of CKD-bone mineral ailment. Increased blood phosphate levels are linked to an increased risk of mortality in hemodialysis patients due to changes in phosphate breakdown and declining renal function as CKD advances.In this setting, according to CKD-mineral bone disease recommendations, it is critical to regulate serum phosphate levels in patients with CKD-mineral bone problem. If dialysis and dietary intervention fail to control blood phosphate levels, the use of phosphate binders is advised. Although phosphate binders are successful in lowering blood phosphate levels by actively binding to dietary phosphate, certain individuals have adverse effects that may restrict their use.These medications also have a significant pill load, which might result in poor treatment compliance. Tenapanor, a novel medication, works by inhibiting the sodium/hydrogen exporter isoform 3 (NHE3), which lowers intestinal phosphate absorption primarily by decreasing passive paracellular phosphate flow. Tenapanor also reduces the expression of the sodium phosphorus 2b transport protein (NaPi2b), which limits active transcellular phosphate absorption compensation. This is considered to be more effective phosphorous absorption regulator and a better target for tailored medication therapy. This clinical study aggregate report explores the currently published studies that have evaluated Tenapanor for the treatment of hyperphosphatemia in end stage renal disease patients on haemodialysis. \u0000Keywords: Tenapanor, phosphate binding agents, hyperphosphatemia, chronic kidney disease, phosphate control, phosphate binders, phosphate absorption, phosphate absorbtion inhibitor.","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":"15 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139528983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6353
Suman Pattanayak, L. Kanthal, Tamanna Afnan, Shalini Shukla, P. Panda
The aim of the present study was to prepare and evaluate Ketoprofen loaded microspheres fabricated with sodium alginate and Carbopol 934 by ion gelation method which enhances the drug residence time into the stomach by adhering to the mucus layer of and control the rate of drug release for longer period of time. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used for its analgesic, anti-inflammatory, and antipyretic (fever-reducing) properties. It belongs to the propionic acid class of NSAIDs and is available in various formulations, including oral tablets, capsules, topical gels, creams, and as an injectable solution. In present study ketoprofen incorporates in mucoadhesive drug delivery system for utilizing its controlled drug delivery up to 12 hrs. In present study prepared microspheres were evaluated for- particle size, entrapment efficiency, percentage yield, morphology, mucoadhesive property, in-vitro drug release property. Keywords: Mucoadhesive microspheres, NSAID, ion gelation method, ketoprofen
{"title":"Preparation and Evaluation of Ketoprofen Loaded Mucoadhesive Microspheres","authors":"Suman Pattanayak, L. Kanthal, Tamanna Afnan, Shalini Shukla, P. Panda","doi":"10.22270/jddt.v14i1.6353","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6353","url":null,"abstract":"The aim of the present study was to prepare and evaluate Ketoprofen loaded microspheres fabricated with sodium alginate and Carbopol 934 by ion gelation method which enhances the drug residence time into the stomach by adhering to the mucus layer of and control the rate of drug release for longer period of time. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is commonly used for its analgesic, anti-inflammatory, and antipyretic (fever-reducing) properties. It belongs to the propionic acid class of NSAIDs and is available in various formulations, including oral tablets, capsules, topical gels, creams, and as an injectable solution. In present study ketoprofen incorporates in mucoadhesive drug delivery system for utilizing its controlled drug delivery up to 12 hrs. In present study prepared microspheres were evaluated for- particle size, entrapment efficiency, percentage yield, morphology, mucoadhesive property, in-vitro drug release property. \u0000Keywords: Mucoadhesive microspheres, NSAID, ion gelation method, ketoprofen","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6372
Leena Muppa, K. Bhavadharini, A. Ramya, R. Bhavadharani
Preterm birth, a major global healthcare concern, is characterized by infants being born before completing 37 weeks of gestation. Accurate diagnosis and effective interventions are critical to managing this complex issue. This abstract provides an overview of the diagnosis and prevention of preterm birth, focusing on risk assessment, diagnostic techniques, and various interventions for mothers and newborns. The diagnostic process involves evaluating risk factors, clinical history, and the assessment of potential membrane rupture. Techniques such as speculum examination, the Nitrazine test, the Fern test, ultrasonography, and the Placental Alpha Microglobulin-1 test play vital roles in identifying membrane rupture and infection. Additional diagnostic markers include cervical ultrasonography and fetal fibronectin testing. Prevention strategies include lifestyle changes, maternal therapies, and antenatal interventions. Smoking cessation programs, low-dose aspirin, antenatal corticosteroid therapy, progesterone supplementation, magnesium sulfate, and antibiotic treatment are employed to reduce the risk of preterm birth. Cervical cerclage, another surgical intervention, is recommended in specific cases. For preterm newborns, immediate and effective care is vital. This includes thermal care, early breastfeeding, infection prevention, and respiratory distress syndrome management. These interventions are crucial in reducing infant mortality and morbidity associated with preterm birth. Efforts to diagnose and prevent preterm birth are essential in improving the well-being of both mothers and their newborns. A comprehensive approach, combining accurate diagnosis and effective interventions, can make a significant impact in reducing the burden of preterm birth on healthcare systems and families. Keywords: Preterm birth, infants, gestation, potential membrane rupture
{"title":"Preterm Birth: A Review of Its Early Diagnosis and Prevention","authors":"Leena Muppa, K. Bhavadharini, A. Ramya, R. Bhavadharani","doi":"10.22270/jddt.v14i1.6372","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6372","url":null,"abstract":"Preterm birth, a major global healthcare concern, is characterized by infants being born before completing 37 weeks of gestation. Accurate diagnosis and effective interventions are critical to managing this complex issue. This abstract provides an overview of the diagnosis and prevention of preterm birth, focusing on risk assessment, diagnostic techniques, and various interventions for mothers and newborns. The diagnostic process involves evaluating risk factors, clinical history, and the assessment of potential membrane rupture. Techniques such as speculum examination, the Nitrazine test, the Fern test, ultrasonography, and the Placental Alpha Microglobulin-1 test play vital roles in identifying membrane rupture and infection. Additional diagnostic markers include cervical ultrasonography and fetal fibronectin testing. Prevention strategies include lifestyle changes, maternal therapies, and antenatal interventions. Smoking cessation programs, low-dose aspirin, antenatal corticosteroid therapy, progesterone supplementation, magnesium sulfate, and antibiotic treatment are employed to reduce the risk of preterm birth. Cervical cerclage, another surgical intervention, is recommended in specific cases. \u0000For preterm newborns, immediate and effective care is vital. This includes thermal care, early breastfeeding, infection prevention, and respiratory distress syndrome management. These interventions are crucial in reducing infant mortality and morbidity associated with preterm birth. Efforts to diagnose and prevent preterm birth are essential in improving the well-being of both mothers and their newborns. A comprehensive approach, combining accurate diagnosis and effective interventions, can make a significant impact in reducing the burden of preterm birth on healthcare systems and families. \u0000Keywords: Preterm birth, infants, gestation, potential membrane rupture","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139621895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.22270/jddt.v14i1.6369
Hope K Fiadjoe, G. Koffuor
Introduction: The global rise in the incidence of diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), and its associated complications have become a public health threat. Besides hyperglycemia, hyperlipidemia has been associated with diabetes due to the defect in insulin secretion and/or action. Medicinal plants are being investigated to discover drug alternatives with better efficacies, lesser adverse effects, and cost-effectiveness. This work investigated the anti-hyperglycemic and anti-hyperlipidemic activity of ethanolic stem bark extract of Blighia unijugata (EBU) in streptozotocin (STZ)-induced diabetic Sprague- Dawley (SD) rats. Method: T2DM was induced in male SD rats by a single intraperitoneal injection of STZ (50 mg/kg in 0.1 M citrate buffer, pH 4.5) and confirmed 72 hours later. EBU (100 and 200 mg/kg) and glibenclamide (5 mg/kg) were administered orally to the diabetic rats (n = 5) for 28 days. The effect of the treatments on fasting blood glucose (FBG), lipid profile, atherogenic predictor indices, and body weight were assessed. Results: EBU treatments significantly reduced (p≤0.001) elevated blood glucose, total cholesterol, triglycerides, and Very Low-Density Lipoprotein cholesterol (VLDL-c, p≤0.001) but increased High-Density Lipoprotein cholesterol (HDL, p≤0.05) compared to the diabetic control. Also, all the atherogenic risk predictor indices were significantly reduced (p≤0.001). In addition, EBU treatment mitigated the significant weight loss (p≤0.01) associated with the diabetic state when compared to the normal control. Conclusion: These findings first report the anti-hyperglycemic, anti-hyperlipidemic, and anti-atherogenic properties of the stem bark of ethanolic extract of Blighia unijugata, and can be further studied and used as an anti-diabetic and anti-hyperlipidemic agent. Keywords: Blighia unijugata; hyperglycemia; atherogenic index; hyperlipidemia; diabetes
{"title":"Ethanolic Stem-Bark Extract of Blighia unijugata Possesses Anti-Hyperglycemic and Anti-Hyperlipidemic Activity in a Streptozotocin-Induced Diabetes Model","authors":"Hope K Fiadjoe, G. Koffuor","doi":"10.22270/jddt.v14i1.6369","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6369","url":null,"abstract":"Introduction: The global rise in the incidence of diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), and its associated complications have become a public health threat. Besides hyperglycemia, hyperlipidemia has been associated with diabetes due to the defect in insulin secretion and/or action. Medicinal plants are being investigated to discover drug alternatives with better efficacies, lesser adverse effects, and cost-effectiveness. This work investigated the anti-hyperglycemic and anti-hyperlipidemic activity of ethanolic stem bark extract of Blighia unijugata (EBU) in streptozotocin (STZ)-induced diabetic Sprague- Dawley (SD) rats. \u0000Method: T2DM was induced in male SD rats by a single intraperitoneal injection of STZ (50 mg/kg in 0.1 M citrate buffer, pH 4.5) and confirmed 72 hours later. EBU (100 and 200 mg/kg) and glibenclamide (5 mg/kg) were administered orally to the diabetic rats (n = 5) for 28 days. The effect of the treatments on fasting blood glucose (FBG), lipid profile, atherogenic predictor indices, and body weight were assessed. \u0000Results: EBU treatments significantly reduced (p≤0.001) elevated blood glucose, total cholesterol, triglycerides, and Very Low-Density Lipoprotein cholesterol (VLDL-c, p≤0.001) but increased High-Density Lipoprotein cholesterol (HDL, p≤0.05) compared to the diabetic control. Also, all the atherogenic risk predictor indices were significantly reduced (p≤0.001). In addition, EBU treatment mitigated the significant weight loss (p≤0.01) associated with the diabetic state when compared to the normal control. \u0000Conclusion: These findings first report the anti-hyperglycemic, anti-hyperlipidemic, and anti-atherogenic properties of the stem bark of ethanolic extract of Blighia unijugata, and can be further studied and used as an anti-diabetic and anti-hyperlipidemic agent. \u0000Keywords: Blighia unijugata; hyperglycemia; atherogenic index; hyperlipidemia; diabetes","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The best solubility enhancement approach is phospholipids complexation. It has been effectively employed by a number of writers to enhance the permeability, oral bioavailability, and solubility of several medicinal substances. The meloxicam is a member of BCS Class II, and because of its poor solubility and high permeability, its clinical application may have been constrained. Therefore, it is necessary to use a method that modifies the biopharmaceutical features. In this work, meloxicam, an NSAID with demonstrated anticancer action, was combined with phospholipid to increase its solubility. Utilizing solvent evaporation, the meloxicam phospholipid complex was produced. Particle size, zeta potential, SEM analysis, in vitro drug release, and solubility were assessed for the produced complex. The results obtained in this study showed the smaller particle size in nanometer range and physical stability with desired zeta potential. Meloxicam's prolonged release from the phospholipid complex is demonstrated by the in vitro drug release investigation. The apparent solubility analysis of meloxicam phospholipid complex. Pure meloxicam showed that the drug's solubility was several times higher than that of the pure form. Hence in conclusion we can say that the phospholipid complexation could be the ideal method for solubility enhancement of drug like meloxicam. Keyword: Meloxicam, phospholipid complex, solubility, drug release
磷脂复合物是提高溶解度的最佳方法。许多学者已经有效地利用磷脂复配来提高多种药物的渗透性、口服生物利用度和溶解度。美洛昔康属于 BCS II 类药物，由于其溶解性差、渗透性高，临床应用可能受到限制。因此，有必要使用一种改变生物制药特征的方法。在这项研究中，一种具有抗癌作用的非甾体抗炎药美洛昔康与磷脂结合，以增加其溶解度。通过溶剂蒸发，生产出了美洛昔康磷脂复合物。对所制复合物的粒度、ZETA电位、SEM分析、体外药物释放和溶解度进行了评估。研究结果表明，美洛昔康磷脂复合物的粒径在纳米范围内较小，且具有理想的 zeta 电位和物理稳定性。体外药物释放研究表明，美洛昔康可从磷脂复合物中延长释放时间。 美洛昔康磷脂复合物的表观溶解度分析。纯美洛昔康的表观溶解度分析表明，该药物的溶解度是纯美洛昔康的数倍。因此，我们可以说磷脂复合物是提高美洛昔康等药物溶解度的理想方法。关键词：美洛昔康 磷脂复合物 溶解度 药物释放
{"title":"Solubility enhancement of meloxicam by phospholipid complexation","authors":"Vaibhav Bhadange, Pravin Kawtikwar, Supriya Jogdand, Ankita Kawtikwar","doi":"10.22270/jddt.v14i1.6390","DOIUrl":"https://doi.org/10.22270/jddt.v14i1.6390","url":null,"abstract":"The best solubility enhancement approach is phospholipids complexation. It has been effectively employed by a number of writers to enhance the permeability, oral bioavailability, and solubility of several medicinal substances. The meloxicam is a member of BCS Class II, and because of its poor solubility and high permeability, its clinical application may have been constrained. Therefore, it is necessary to use a method that modifies the biopharmaceutical features. In this work, meloxicam, an NSAID with demonstrated anticancer action, was combined with phospholipid to increase its solubility. Utilizing solvent evaporation, the meloxicam phospholipid complex was produced. Particle size, zeta potential, SEM analysis, in vitro drug release, and solubility were assessed for the produced complex. The results obtained in this study showed the smaller particle size in nanometer range and physical stability with desired zeta potential. Meloxicam's prolonged release from the phospholipid complex is demonstrated by the in vitro drug release investigation. The apparent solubility analysis of meloxicam phospholipid complex. Pure meloxicam showed that the drug's solubility was several times higher than that of the pure form. Hence in conclusion we can say that the phospholipid complexation could be the ideal method for solubility enhancement of drug like meloxicam. \u0000Keyword: Meloxicam, phospholipid complex, solubility, drug release","PeriodicalId":506928,"journal":{"name":"Journal of Drug Delivery and Therapeutics","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139622756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：